Drugs / hCAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02349698 | Dec 2014 → Dec 2022 | leukemia, lymphoma | Southwest Hospital, China | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hCAR-T | “In this study, we developed a humanized anti-CD19 scFv CAR-T (hCAR-T) to treat patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).” PMID 31732519 ↗ Nov 2019 |
| Action | Deplete | “Preclinical studies have demonstrated effective killing of CD19 target cells.” NCT02349698 ↗ |
| Modality | Cell therapy | “T cells modified with hCAR” PMID 31732519 ↗ Nov 2019 |
| Target | CD19 | “T cells modified with CD19 targeted chimeric antigen receptor.” NCT02349698 ↗ |